NMOSD patient registry to help study future treatments
Part of Brain & nervous system, Eyes & vision, Immune system & allergy clinical trials.
This is a registry that collects health information from adults with neuromyelitis optica spectrum disorder (NMOSD). It aims to better understand NMOSD and support future research, including studies of emerging therapies.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with NMOSD using the 2015 diagnostic guidelines.
- You are 18 years old or older.
- You are willing to share personal information with the study team.
- You have not had a confirmed NMOSD symptom flare (neuro-episode) in the last 12 weeks.
- You are not taking part in a double-blind randomized NMOSD drug trial at the same time (but other observational studies may be okay).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This registry collects health and relapse information from adults with AQP4-positive NMOSD who are taking C5-blocking medicines to prevent long-term relapses. It helps researchers better understand treatment patterns and outcomes in real-world care.
This trial compares several medications to see which works best for NMOSD, an autoimmune disease that can cause vision loss and paralysis. You must have a specific antibody (AQP4-IgG) to join.
This study follows people with NMOSD (a rare autoimmune disease affecting the brain and spinal cord) to learn more about the condition and how it affects patients over time. It involves regular check-ups and MRI scans, with the goal of improving future care and treatment.
This study uses MRI scans to look for hidden disease activity in people with NMOSD who feel stable and are already on rituximab. The goal is to catch any signs of damage early, which might help prevent future disability.
This is a registry study that collects health information from people with multiple sclerosis and related conditions. By joining, you help researchers better understand these diseases and improve future treatments.
This trial tests a new antibody-based medicine to help people recover from an acute attack of neuromyelitis optica spectrum disorder (NMOSD), a condition that causes inflammation in the eyes and spinal cord. If you are having a recent flare-up and are already getting or planning to get steroid treatment, this study might offer an additional option to reduce damage and speed recovery.
Hear when a new Neuromyelitis Optica Spectrum Disorder trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.